Conway Robert G 4
4 · AGILE THERAPEUTICS INC · Filed Aug 26, 2024
Insider Transaction Report
Form 4
Conway Robert G
SVP Ent Planning & Info Mgt
Transactions
- Disposition to Issuer
Common Stock
2024-08-26$1.52/sh−10,125$15,390→ 3,404 total - Disposition to Issuer
Common Stock
2024-08-26$1.52/sh−3,404$5,174→ 0 total
Footnotes (2)
- [F1]Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 10,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $15,390, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.
- [F2]Upon the consummation of the Merger, pursuant to the Merger Agreement, 3,404 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $5,174, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.